MilliporeSigma Matches 100% of U.S. Electricity Consumption With Renewable Energy

MilliporeSigma Matches 100% of U.S. Electricity Consumption With Renewable Energy

MilliporeSigma is taking 68 megawatts of the project’s 350 MW capacity to match 100% of the company’s U.S. electricity consumption with renewable energy.
MilliporeSigma is taking 68 megawatts of the project’s 350 MW capacity to match 100% of the company’s U.S. electricity consumption with renewable energy.

MilliporeSigma is taking 68 megawatts of the project’s 350 MW capacity to match 100% of the company’s U.S. electricity consumption with renewable energy.

Wednesday, July 20, 2022 - 9:00am

CAMPAIGN: Sustainable Operations

CONTENT: Article

  • Offsets 118,000 metric tons of CO2
  • Reinforces the company's long-term commitment to more sustainable operations 

WHO: MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, along with Enel Green Power. 

WHAT: MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has matched 100% of its U.S. electricity consumption with renewable energy.

MilliporeSigma is taking 68 megawatts (MW) of the Azure Sky Wind and Storage project’s 350 MW capacity as an anchor buyer within the Net Zero Consortium for Buyers. This project, which is now operational, offsets 118,000 metric tons of CO2 from MilliporeSigma’s operations.

WHEN: This project is now operational, offsetting 118,000 metric tons of CO2 from the company’s operations.

In 2021, the company participated in one of the largest aggregation deals in the world: a 12-year, off-site, virtual power purchase agreement with Enel Green Power. This commitment applied the concept of additionality to the company’s renewable energy strategy by enabling the construction of the Azure Sky Wind and Storage project in Texas.

WHY: This project directly contributes to the company’s goals of sourcing 80% of global electricity from renewables by 2030 as well as its commitment to being climate neutral by 2040. For more information about MilliporeSigma’s commitment to managing the environmental impact of its operations, click here.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

About the Life Science Business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 26,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck KGaA, Darmstadt, Germany generated sales of € 19.7 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.